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Background/Aims: Antiviral therapy (AVT) reduces the risk 
of hepatocellular carcinoma (HCC) development in patients 
with chronic hepatitis B (CHB). This multicenter retrospective 
study investigated the effects of AVT and hepatitis B virus 
(HBV)-related factors on the risk of HCC development in a 
cohort with heterogeneous HBV status. Methods: A total of 
1,843 patients with CHB from two institutions were included 
in this study. Ultrasound and laboratory tests, including the 
α-fetoprotein test, were conducted regularly to detect HCC 
development. Results: The mean age of our study popula-
tion (1,063 men and 780 women) was 49.4 years. Cirrhosis 
was identified in 617 patients (33.5%). During follow-up 
(median, 42.5 months), 81 patients developed HCC (1.39% 
per person-year). A total of 645 patients (35.0%) received 
ongoing AVT at enrollment. Ongoing AVT was not significantly 
associated with the risk of HCC development (all p>0.05). 
HBV-related variables (HBV DNA level, hepatitis B e antigen 
status, and alanine aminotransferase level) were also not 
significantly associated with the risk of HCC development (all 
p>0.05). In contrast, cirrhosis was significantly associated 
with the risk of HCC development, regardless of adjustment 
(adjusted hazard ratio=4.098 to 7.020; all p<0.05). Cirrhosis 
significantly predicted the risk of HCC development in sub-
groups with and without ongoing AVT at enrollment, regard-
less of adjustment. Conclusions: Our study showed that 
cirrhosis, not AVT and HBV-related variables, was associated 
with HCC development in a cohort of patients with heteroge-
neous HBV status. Our results may help clinicians apply indi-
vidualized surveillance strategies according to fibrotic status 
in patients with CHB. (Gut Liver 2019;13:197-205)
Key Words: Liver cirrhosis; Fibrosis; Antiviral therapy; Hepati-
tis B; Clinical outcome
INTRODUCTION
As persistently high levels of hepatitis B virus (HBV) replica-
tion are closely associated with an increased risk for liver cirrho-
sis and hepatocellular carcinoma (HCC),1 replication-suppressing 
antiviral therapy (AVT) is the mainstay of current management 
for chronic hepatitis B (CHB).2,3 This is strongly supported by a 
landmark randomized placebo-controlled trial by Liaw et al.,4 
which stratified CHB patients with advanced fibrosis or cirrhosis 
into lamivudine and placebo arms and found a significant ben-
efit against HCC development in the lamivudine arm. Similarly, 
several subsequent meta-analyses have confirmed the beneficial 
influence of AVT in the long-term outcomes of CHB patients.5,6 
Due to this proven benefit of AVT against HCC development, 
no randomized placebo-controlled trials of drugs with a high 
genetic barrier, including entecavir or tenofovir, are available. 
Accordingly, recent studies have adopted cohorts of untreated 
historical controls to investigate the influence of drugs with 
a high genetic barrier on HCC development. Among several 
historical control-matched studies,7-10 a large, retrospective-pro-
spective study by Wong et al.7 included 1,446 patients treated 
with entecavir and 424 untreated historical controls. In this 
study, entecavir significantly reduced the 5-year incidence rates 
of HCC (hazard ratio [HR]=0.55), hepatic events (HR=0.51), liver-
related mortality (HR=0.26), and all-cause mortality (HR=0.34) 
in patients with liver cirrhosis but not in the entire patient 
population.7 
Although randomized, placebo-controlled trials and historical 
control-matched studies have shown that AVT reduces the risk 
of HCC development in CHB patients (particularly those with 
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liver cirrhosis), the status of HBV infection is inevitably hetero-
geneous within CHB cohorts at any given time in the real-world 
setting. CHB patients with a high viral load but who are in the 
immune tolerant phase or with low viral load in the inactive 
carrier phase do not require AVT, whereas those in the immune 
clearance or reactivation phases require AVT to prevent disease 
progression. Thus, there is a possibility that the different clinical 
characteristics of each HBV status can potentially bias the influ-
ence of AVT on HCC development if untreated cohorts or his-
torical controls are not available. Indeed, a recent study by Cho 
et al.11 showed that HCC risk remained higher in patients who 
even achieved complete virological remission than in patients 
with an inactive carrier status.11 Furthermore, another recent 
study by Park et al.12 showed that AVT was independently asso-
ciated with a higher risk of HCC development due to the differ-
ent baseline characteristics between CHB patients treated with 
AVT and those who did not receive AVT. 
Thus, in this multicenter retrospective study, we investigated 
the influence of AVT as well as of HBV-related variables on the 
risk of HCC development in a cohort with heterogeneous HBV 
status.
MATERIALS AND METHODS
1. Patients
From January 2013 to December 2013, consecutive CHB 
patients from two institutions (Severance Hospital, Yonsei Uni-
versity and CHA Bundang Medical Center, CHA University) 
were considered eligible for this study. CHB was defined as the 
persistent presence of serum hepatitis B surface antigen (HBsAg) 
for more than 6 months. The exclusion criteria were as follows: 
current or past history of HCC at enrollment, HCC development 
within 6 months after enrollment, current or past history of he-
patic decompensation at enrollment, Child-Pugh B and C class, 
coinfection with hepatitis C and/or human immunodeficiency vi-
rus, liver transplant status, significant alcohol consumption, and 
insufficient clinical and laboratory data (Supplementary Fig. 1). 
This study was performed in accordance with the ethical 
guidelines of the 1975 Declaration of Helsinki and was ap-
proved by the Institutional Review Boards at Severance Hospital 
(2018-0764-001) and at CHA Bundang Medical Center (2018-
04-050). Written informed consent from enrolled patients was 
waived due to the retrospective nature of this study.
2. Baseline work-up and follow-up
At baseline, patients provided a full medical history; under-
went physical examination and routine blood chemistry; were 
assessed for hepatitis B e antigen (HBeAg) and its antibody, se-
rum HBV DNA level, and α-fetoprotein (AFP) levels, underwent 
ultrasonography, and were screened for HCC. If no evidence of 
HCC was detected, patients were followed up every 6 months 
with ultrasonography and laboratory work-up, including AFP 
to screen for HCC. HBsAg and HBeAg were measured using 
standard enzyme-linked immunosorbent assays (Abbott Labora-
tories, Chicago, IL, USA). HBV DNA levels were measured using 
a real-time polymerase chain reaction assay (Amplicor HBV 
Monitor Test; Roche Diagnostics, Basel, Switzerland; detection 
limit approximately 20 IU/mL). 
3. Antiviral therapy
During the study, AVT was initiated based on the treatment 
guidelines developed by the Korean Association for the Study 
of the Liver.13 In cases of virologic breakthrough (defined as >1 
log10 IU/mL increase in serum HBV DNA level from nadir on 
two consecutive tests) or genotypic mutations, rescue therapy 
was applied, if appropriate.
4. Diagnosis of cirrhosis and HCC
Cirrhosis was diagnosed based on liver histology, ultrasono-
graphic findings or clinical signs of portal hypertension, such 
as the presence of ascites, esophageal or gastric varices, and he-
patic encephalopathy.14 HCC was diagnosed based on radiologic 
findings from computed tomography or/and magnetic reso-
nance imaging or based on histologic evidence, in accordance 
with the guideline of the American Association for the Study of 
Liver Diseases.15
5. Statistical analyses
Data are expressed as the mean±standard deviation, median 
with range, or number (%) as appropriate. Differences among 
continuous and categorical variables were examined for statisti-
cal significance using the Student t-test (or the Mann-Whitney 
U-test, if appropriate) and the chi-square test (or Fisher exact 
test, if appropriate), respectively. Person-years of follow-up 
were calculated from the date of study entry to either the onset 
of HCC or the last follow-up date.
Patients were censored at the time of HCC development or at 
the last follow-up. The incidence rate was calculated by dividing 
the number of patients with newly diagnosed HCC by the cor-
responding person-years. Cumulative HCC incidence rates were 
analyzed using the Kaplan-Meier method and compared with 
the log-rank test. To estimate independent predictors of HCC 
development, univariate and subsequent multivariate Cox pro-
portional hazard regression analyses were performed. HRs and 
corresponding 95% confidence intervals (CIs) were used where 
indicated. Various multivariate logistic regression analyses were 
applied to determine the independent associations among HBV-
related variables (HBV DNA level, HBeAg status, and alanine 
aminotransferase [ALT] level), cirrhosis, and the risk of HCC de-
velopment.
All statistical analyses were performed using SPSS software 
version 18.0 (SPSS Inc., Chicago, IL, USA). A p-value <0.05 was 
considered to indicate statistical significance. 
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RESULTS
1. Baseline characteristics 
Among 4,850 patients with CHB from two centers (2,442 
patients from Severance Hospital, Yonsei University and 2,408 
patients from CHA Bundang Medical Center, CHA University) 
who were considered eligible for this study, 3,007 patients were 
excluded according to our exclusion criteria. Finally, 1,843 
patients were selected for statistical analysis (804 patients from 
Severance Hospital and 1,039 patients from CHA Bundang 
Medical Center) (Supplementary Fig. 1).
The baseline characteristics of the study population at enroll-
ment are summarized in Table 1. The mean age of our study 
population (1,063 men and 780 women) was 49.4 years. Cir-
rhosis was identified in 617 patients (33.5%), and 453 patients 
(24.6%) were HBeAg positive. The mean HBV DNA and ALT 
levels were 2.8 log10 IU/mL and 44.4 IU/L, respectively. A total 
of 645 patients (35.0%) received ongoing AVT at enrollment, 
which included lamivudine (n=62, 9.6%), telbivudine (n=23, 
3.6%), clevudine (n=10, 1.6%), adefovir (n=89, 13.8%), entecavir 
(n=315, 48.8%), tenofovir (n=44, 6.8%), or a combination regi-
men (n=102, 15.8%). 
2. Follow-up and HCC development
The median follow-up period of the entire study population 
was 42.5 months (range, 6.1 to 51.7 months), constituting a to-
tal of 5,845 person-years. The follow-up periods of the two in-
stitutions were statistically similar (median 41.6 months vs 43.1 
months, p=0.438). During follow-up, 81 patients (49 [60.5%] 
from Severance Hospital and 32 [39.5%] from CHA Bundang 
Medical Center) developed HCC (1.39% per 1 person-year). The 
cumulative incidence rates of HCC at 1 and 3 years were 0.6% 
and 3.4%, respectively. Of the 81 patients who developed HCC, 
39 (48.1%) received AVT at enrollment, and 35 (43.2%) initi-
ated AVT after enrollment. The remaining seven (8.7%) patients 
without AVT during the study period experienced HCC devel-
opment (two with minimally increased ALT levels [1–2× upper 
limit of normal] and five with liver cirrhosis, possibly from 
HBeAg-negative CHB phase).
3. Comparisons of baseline characteristics according to 
AVT status
To investigate the reason for the similar or even higher risk 
of HCC development in patients with ongoing AVT at enroll-
ment when compared with those without AVT, we compared 
the baseline characteristics of these two groups (Table 2). Pa-
tients receiving AVT at enrollment were significantly older 
(mean 50.3 years vs 48.9 years) and had a higher incidence 
of diabetes mellitus (13.3% vs 10.0%) and cirrhosis (42.8% vs 
28.5%), lower AFP level (mean 4.5 ng/mL vs 6.9 ng/mL), lower 
HBV DNA level (mean 1.6 log IU/mL vs 3.4 log IU/mL), lower 
aspartate aminotransferase (AST) level (mean 28.3 IU/L vs 42.2 
IU/L), lower ALT level (mean 28.2 IU/L vs 53.1 IU/L), and lower 
platelet count (mean 163×109/L vs 179×109/L) than patients not 
engaged in AVT at enrollment (all p<0.05). 
We also compared the baseline characteristics between pa-
tients who initiated AVT after enrollment and those naïve to 
AVT during the study period (Supplementary Table 1). Patients 
Table 1. Baseline Characteristics 
Variable
All 
(n=1,843)
Yonsei University
(n=804, 43.6%)
Cha University
(n=1039, 56.4%)
 p-value
Demographic 
   Age, yr 49.4±11.4 52.4±10.7 47.1±11.3 <0.001
   Male sex 1,063 (57.7) 443 (55.1) 620 (59.7) 0.051
   Diabetes mellitus  206 (11.2) 44 (5.5) 162 (15.6) <0.001
   Cirrhosis  617 (33.5) 379 (47.1) 238 (22.9) <0.001
Laboratory 
   α-Fetoprotein, ng/mL 6.1±22.4 5.7±21.5 6.3±23.1 0.579
   HBeAg positivity 453 (24.6) 154 (19.2) 299 (28.8) <0.001
   HBV DNA, log IU/mL 2.8±2.1 2.7±2.0 2.9±2.2 0.021
   Aspartate aminotransferase, IU/L 37.3±57.6 33.7±43.7 40.1±66.4 0.013
   Alanine aminotransferase, IU/L 44.4±90.5 39.2±70.1 48.5±103.5 0.022
   Serum albumin, g/dL 4.4±0.4 4.3±0.3 4.5±0.4 <0.001
   Total bilirubin, mg/dL 0.8±0.5 0.9±0.5 0.8±0.4 <0.001
   Platelet count, 109/L 174±60 168±64 178±57 <0.001
Ongoing antiviral therapy 645 (35.0) 278 (34.6) 367 (35.3) 0.768
Data are presented as mean±SD or number (%).
HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.
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who initiated AVT after enrollment were significantly more 
likely to have cirrhosis (42.0% vs 19.1%) and HBeAg positivity 
(41.5% vs 10.3%), higher AFP level (mean 10.5 ng/mL vs 4.4 
ng/mL), higher HBV DNA level (mean 4.2 log IU/mL vs 2.9 log 
IU/mL), higher AST level (mean 62.0 IU/L vs 28.4 IU/L), higher 
ALT level (mean 81.3 IU/L vs 33.6 IU/L), lower serum albumin 
level (mean 4.3 g/dL vs 4.4 g/dL), higher total bilirubin level 
(mean 0.9 vs 0.8), and lower platelet count (mean 162×109/L vs 
192×109/L) than patients naïve to AVT during the study period 
(all p<0.05).
4. Association between HBV-related variables and risk of 
HCC development
The HRs of HCC development by HBV-related variables 
(HBV DNA level, HBeAg status, and ALT level) and differently 
adjusted models are summarized in Table 3. All three variables 
were not significantly associated with the risk of HCC develop-
ment, regardless of adjustment (all p>0.05). When the study 
population was divided into two groups with and without on-
going AVT (n=645 [35.0%] and n=1,198 [65.0%], respectively), 
there was also no significant association between HBV-related 
variables and the risk of HCC development in both subgroups (all 
p>0.05) (Table 3). 
In the entire cohort, the cumulative HCC incidence rates were 
not significantly different according to HBV DNA level (p=0.821 
by log-rank test, HBV DNA ≤100 IU/mL [n=986, 53.5%] vs 
101–10,000 IU/mL [n=470, 25.5%] vs 10,001–1,000,000 IU/mL 
[n=178, 9.7%] vs >1,000,000 IU/mL [n=209, 11.3%]) (Supple-
mentary Fig. 2A), HBeAg status (p=0.947 by log-rank test, posi-
tive [n=453, 24.6%] vs negative [n=1,390, 75.4%]) (Supplemen-
tary Fig. 2B), and ALT level (p=0.325 by log-rank test, ≤40 IU/L 
[n=1,364, 74.0%] vs 41–80 IU/L [n=338, 18.3%] vs 81–400 IU/L 
[n=123, 6.7%] vs >400 IU/L [n=18, 1.0%]) (Supplementary Fig. 
2C). 
5. Association between ongoing AVT and risk of HCC devel-
opment
The HRs of HCC development by ongoing AVT and differ-
ently adjusted models are summarized in Table 4. In the entire 
population, ongoing AVT did not show a significant association 
with the risk of HCC development after adjustments (all p>0.05). 
The association between ongoing AVT and risk of HCC devel-
opment was assessed in each institution (Supplementary Table 
2), and ongoing AVT was not associated with the risk of HCC 
development at Severance Hospital (n=804 [43.6%]) (all p>0.05). 
Although ongoing AVT showed an independent positive as-
sociation with a higher risk of HCC development in minimally 
adjusted models in the subgroup from CHA Bundang Medical 
Center (n=1,039 [56.4%]) (HR=2.265 [95% CI, 1.113 to 4.611] 
in model 1, which adjusted for age and gender, and HR=2.217 
[95% CI, 1.089 to 4.514] in model 2, which adjusted for age, 
gender, and diabetes mellitus; all p<0.05), the significance was 
attenuated in further models that adjusted for more covariates. 
The cumulative incidence rates of HCC in patients with ongoing 
AVT (0.9% at 1 year and 4.2% at 3 years) tended to be higher 
than those in patients without ongoing AVT (0.3% at 1 year and 
2.8% at 3 years), but these differences did not show any statisti-
cal significance (p=0.076 by log-rank test) (Fig. 1). 
6. Association between cirrhosis and risk of HCC develop-
ment
The HRs of HCC development by cirrhosis and differently 
Table 2. Comparison of Baseline Characteristics between Patients with and without Ongoing AVT at Enrollment
Variable
With ongoing AVT at enrollment
(n=645, 35.0%)
Without ongoing AVT at enrollment
(n=1,198, 65.0%)
p-value
Demographic
   Age, yr 50.3±10.4 48.9±11.8 0.011
   Male sex 387 (60.0) 676 (56.4) 0.152
   Diabetes mellitus 86 (13.3) 120 (10.0) 0.036
   Cirrhosis 276 (42.8) 341 (28.5) <0.001
Laboratory 
   α-Fetoprotein, ng/mL 4.5±14.1 6.9±25.8 0.009
   HBeAg positivity 176 (27.3) 277 (23.1) 0.054
   HBV DNA, log IU/mL 1.6±1.0 3.4±2.2 <0.001
   Aspartate aminotransferase, IU/L 28.3±26.8 42.2±68.3 <0.001
   Alanine aminotransferase, IU/L 28.2±31.2 53.1±109.0 <0.001
   Serum albumin, g/dL 4.4±0.4 4.4±0.3 0.211
   Total bilirubin, mg/dL 0.9±0.5 0.8±0.4 0.901
   Platelet count, 109/L 163±57 179±62 <0.001
Data are presented as mean±SD or number (%).
AVT, antiviral therapy; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.
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adjusted models are summarized in Table 5. In the entire popu-
lation, cirrhosis showed a significant association with the risk 
of HCC development regardless of various adjustments (unad-
justed HR=8.454 [95% CI, 4.824 to 14.813], adjusted HR=4.098 
to 7.020; all p<0.05). When the study population was stratified 
into two subgroups based on AVT status at enrollment, cirrhosis 
was a significant risk factor for HCC development in both sub-
groups, regardless of the adjustments (Supplementary Table 3).
The association between cirrhosis and risk of HCC develop-
ment was assessed at each institution (Supplementary Table 4). 
Cirrhosis was significantly associated with the risk of HCC de-
velopment at Severance Hospital regardless of adjustments (un-
adjusted HR=4.795 [95% CI 2.327 to 9.883], adjusted HR=3.380 
to 4.435; all p<0.05), except for the borderline statistical sig-
nificance observed in model 5, which adjusted for age, gender, 
diabetes mellitus, laboratory tests, AVT at enrollment, and AVT 
initiation after enrollment (HR=2.228 [95% CI, 0.966 to 5.141]; 
p=0.060). In the subgroup from CHA Bundang Medical Center, 
cirrhosis was independently associated with the risk of HCC 
development regardless of adjustments (unadjusted HR=14.021 
[95% CI, 5.770 to 34.070], adjusted HR=7.237 to 11.347; all 
p<0.001). 
The cumulative incidence of HCC in the subgroup with cir-
rhosis was significantly higher than that of the subgroup with-
out cirrhosis (p<0.001 by log-rank test) (Fig. 2). The cumulative 
incidence rate of HCC in the subgroup with cirrhosis at 1 and 3 
years was 1.5% and 7.6%, respectively, whereas in the subgroup 
Table 4. HRs of Hepatocellular Carcinoma Development by Ongoing 
Antiviral Therapy and Differently Adjusted Models
Model HR 95% CI p-value
Unadjusted 1.480 0.957–2.291 0.078 
Adjusted
   Model 1 1.475 0.952–2.283 0.082 
   Model 2 1.472 0.951–2.280 0.083 
   Model 3 1.141 0.735–1.771 0.557 
   Model 4 1.356 0.819–2.245 0.236 
   Model 5 1.352 0.817–2.237 0.241 
HR, hazard ratio; CI, confidence interval; HBeAg, hepatitis B e anti-
gen; HBV, hepatitis B virus.
Model 1, age and gender; model 2, model 1 + diabetes mellitus; mod-
el 3, model 2 + cirrhosis; model 4, model 3 + α-fetoprotein, HBeAg 
positivity, HBV DNA, aspartate aminotransferase, alanine amino-
transferase, serum albumin, total bilirubin, and platelet count; model 
5, model 4 + institution.
Table 5. HRs of Hepatocellular Carcinoma Development by Cirrhosis 
and Differently Adjusted Models (All Study Participants)
Model HR 95% CI p-value
   Unadjusted 8.454 4.825–14.813 <0.001
   Adjusted
      Model 1 6.957 3.957–12.231 <0.001
      Model 2 7.020 3.992–12.347 <0.001
      Model 3 5.257 2.795–9.885 <0.001
      Model 4 5.117 2.754–9.733 <0.001
      Model 5 4.337 2.301–8.177 <0.001
      Model 6 4.095 2.148–7.807 <0.001
HR, hazard ratio; CI, confidence interval; HBeAg, hepatitis B e anti-
gen; HBV, hepatitis B virus; AVT, antiviral therapy.
Model 1, age and gender; model 2, model 1 + diabetes mellitus; mod-
el 3, model 3 + α-fetoprotein, HBeAg positivity, HBV DNA, aspartate 
aminotransferase, alanine aminotransferase, serum albumin, total 
bilirubin, and platelet count; model 4, model 3 + AVT at enrollment; 
model 5, model 4 + AVT after enrollment; model 6, model 5 + insti-
tution.
Fig. 2. Cumulative incidence rates of hepatocellular carcinoma (HCC) 
based on cirrhosis. The cumulative incidence rate of HCC in the 
subgroup with cirrhosis was significantly higher than that of the sub-
group without cirrhosis (p<0.001 by the log-rank test).
Fig. 1. Cumulative incidence rates of hepatocellular carcinoma (HCC) 
based on antiviral therapy (AVT) status at enrollment. The cumula-
tive HCC incidence rates were not significantly different based on the 
AVT status at enrollment (p=0.076 by the log-rank test).
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without cirrhosis, the rate was 0.1% and 1.1%, respectively. 
DISCUSSION
In this multicenter study comprising CHB patients with hetero-
geneous HBV status, AVT did not significantly predict HCC de-
velopment after adjusting for other variables. In addition, HBV-
related variables such as HBV DNA, HBeAg, and ALT level were 
not associated with the risk of HCC development. In contrast, 
liver cirrhosis was significantly associated with the risk of HCC 
development regardless of adjustments (unadjusted HR=8.454, 
adjusted HR=4.098–7.020). Accordingly, the cumulative inci-
dence of HCC in the subgroup with cirrhosis was significantly 
higher than that in the subgroup without cirrhosis.
Several studies have demonstrated a decrease in HCC develop-
ment in patients with CHB who received AVT compared with 
historical controls who were unable to obtain AVT.4,8,16-20 Howev-
er, in some previous studies that included patients receiving AVT 
and those in the inactive or immune tolerant phase who did not 
require AVT, AVT did not show a beneficial effect in preventing 
HCC development. A previous study21 that investigated predic-
tors of HCC development in heterogeneous CHB cohorts showed 
that AVT was not significantly associated with HCC risk. By 
contrast, the degree of fibrotic burden, which was defined using 
transient elastography, was selected as an independent predictor 
of HCC development. In another study by Park et al.,12 AVT was 
a significant predictor of HCC development, contrary to expecta-
tion, probably due to the unfavorable baseline characteristics of 
patients with AVT compared to those of patients without AVT; 
patients with AVT presented a higher body mass index, higher 
total bilirubin, higher AST level, lower serum albumin level, and 
higher degree of fibrotic burden than patients without AVT. We 
also investigated the influence of AVT on HCC development in 
a cohort with heterogeneous CHB status and found that, after 
adjusting for multiple variables, AVT showed no association 
with HCC development. More importantly, there was a trend of 
a higher risk of HCC development in patients receiving AVT at 
enrollment than in those not receiving AVT at enrollment. 
Among 707 patients who did not receive AVT during the 
study period, seven patients developed HCC in our study. These 
patients who were not candidates for AVT according to Korean 
guidelines13 had minimally elevated ALT level or liver cirrhosis, 
possibly due to the HBeAg-negative CHB phase, indicating the 
importance of careful surveillance even in patients who do not 
undergo AVT. Regarding this issue, several studies showed that 
the indications of AVT should be expanded to individuals with 
lower serum HBV DNA levels and/or lower serum ALT levels.22,23 
In addition, recent studies showed that HCC or progression to 
cirrhosis can develop even in patients in the immune tolerance 
or inactive carrier phases.24-26 However, no patients in the im-
mune tolerance or inactive carrier phases developed HCC in our 
study, probably due to relatively small sample size of patients in 
these CHB phases in our study.
Because patients with worse baseline characteristics might 
have a higher chance of receiving AVT than those with favor-
able predictors such as low viral titer and normal ALT level, 
careful interpretation is needed regarding the influence of AVT 
when assessing mixed CHB cohorts. Indeed, in our cohort, com-
pared with patients without AVT at enrollment, those with AVT 
had more confounding factors that could also be associated 
with an increased risk of HCC development, such as older age, 
higher incidence of cirrhosis, higher AFP level, higher total bili-
rubin level, and lower platelet level. The observed unfavorable 
characteristics in patients with AVT were quite similar to those 
reported by Park et al.,12 as mentioned above. This phenomenon 
of inevitably imbalanced characteristics between patients with 
and without AVT might explain the varying influence of AVT 
on the risk of HCC development in heterogeneous HBV cohorts, 
which, in turn, suggests that cohorts with heterogeneous HBV 
status should be divided into subgroups with and without AVT 
and that the disease course of each cohort should be investi-
gated separately.
In our study, we were able to clearly show that patients with 
cirrhosis had a higher risk for HCC than those without cirrhosis 
in a cohort with heterogeneous CHB status, regardless of AVT 
status. Several studies showed that appropriate AVT with po-
tent antiviral agents cannot completely abolish the risk of HCC 
development. These studies also demonstrated that cirrhosis is 
a significant risk factor for HCC incidence during AVT.8,20,27-30 
Moreover, several reports used recently developed noninvasive 
imaging and serum surrogates to assess the degree of liver fi-
brosis and showed that fibrotic burden is a significant risk fac-
tor for HCC development.31-37 A previous study by Kim et al.,38 
which used transient elastography to assess fibrotic burden, also 
reported a similar finding–the degree of liver fibrosis, rather 
than potent AVT with appropriate rescue therapy, was associ-
ated with the risk of HCC development. In another study by Kim 
et al.,34 advanced fibrosis as defined by transient elastography 
was an important risk factor for HCC development, even in pa-
tients without clinical evidence of cirrhosis. They also showed 
that cirrhosis was an independent HCC risk factor in patients 
with and without AVT, which is consistent with the findings of 
our current study. Taken together, these data suggest that be-
cause patients with cirrhosis have a higher risk of HCC develop-
ment regardless of AVT status, clinicians should actively assess 
the degree of liver fibrosis to develop an individual surveillance 
strategy for these patients.
In our study, well-known conventional risk factors of HCC 
development, such as HBV DNA level, HBeAg status, and ALT 
level, failed to show significant correlations with the risk of 
HCC development. Although these HBV-related variables have 
been useful in determining the disease state and in predicting 
clinical outcomes in patients with HBV infection until recently, 
this approach might be no longer appropriate in this era of ac-
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tive and potent AVT, especially when there is a need to predict 
clinical outcomes, including HCC development. Indeed, based 
on current guidelines, the higher risk of disease progression due 
to unfavorable characteristics such as high viral load and high 
ALT level can be significantly reduced due to the current potent 
AVTs,2,3,13,22 which suppress HBV DNA potently and rapidly nor-
malize ALT. Therefore, it is not surprising that the influence of 
these conventional risk factors on the risk of HCC development 
was attenuated in our study. 
We are also aware of several limitations of our study. First, 
our findings might have been influenced by the relatively short 
follow-up period (median, 42.5 months) because we tried to in-
clude patients treated with drugs with a high genetic barrier to 
reflect the current era of potent AVTs, including entecavir-based 
(48.8%) and tenofovir-based (6.8%) regimens, which were ap-
proved in Korea in 2007 and 2012, respectively. Thus, a subse-
quent study with a longer follow-up and with homogenous use 
of drugs with a high genetic barrier would be required. Second, 
the simple stratification of cirrhosis based on ultrasound might 
have biased our results. As is commonly known, the diagnostic 
accuracy of ultrasound for cirrhosis has been mixed. Indeed, 
a recent study has shown that compared to transient elastog-
raphy, ultrasonographic evaluation can miss the diagnosis of 
early compensated cirrhosis.34 Thus, further studies that use 
more recent and accurate noninvasive imaging surrogates to 
assess the stepwise increase in fibrotic burden are required to 
validate our results. Third, more detailed information regarding 
fibrotic burden based on either histology or transient elastogra-
phy was not available. However, because fibrotic burden can be 
variable even in patients undergoing AVT, future studies with 
fibrotic burden-matched cohorts that compare patients with and 
without AVT might provide more relevant clinical implications. 
Finally, the baseline characteristics of patients from two institu-
tions were significantly different. Accordingly, the proportion of 
patients who developed HCC was significantly different between 
the institutions. However, we tried to reduce the potential bias 
by adjusting for institutions after adjusting HBV-related vari-
ables, AVT, and cirrhosis to estimate risk of HCC development. 
The overall results were similar between the two institutions, 
which might indicate the reproducibility of our results regard-
less of the baseline characteristics of the study population. 
In conclusion, in our study, AVT as well as HBV-related 
variables, including HBV DNA level, HBeAg status, and ALT 
level, were unexpectedly not associated with HCC development. 
Thus, to prevent the biased influence of AVT on the risk of HCC 
development, it would be better to analyze the separated cohort 
based on AVT and not the heterogeneous CHB cohorts in future 
HBV studies. Furthermore, in our study, patients with cirrhosis 
had a higher risk of HCC development, indicating that cirrhosis, 
not AVT, can predict HCC development in cohorts with het-
erogeneous HBV status. Our results may help clinicians apply 
individualized surveillance strategies according to fibrotic status 
in patients with CHB.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was 
reported.
ACKNOWLEDGEMENTS 
This study was supported by the Basic Science Research 
Program through the National Research Foundation of Korea 
funded by the Ministry of Science, ICT & Future Planning 
(2016R1A1A1A05005138), and the Ministry of Education, 
(2015R1D1A1A01058653). The funders had no role in the 
study design, data collection and analysis, decision to publish, 
or preparation of the manuscript. The authors are grateful to 
Dong-Su Jang, (Medical Illustrator, Medical Research Support 
Section, Yonsei University College of Medicine, Seoul, Republic 
of Korea) for his help with the figures.
Author contributions: Conception and design: S.U.K. and 
S.H.A.; development of methodology: S.U.K., S.H.A., and M.N.K.; 
acquisition, analysis and interpretation of data: all authors; 
writing, review, and/or revision of the manuscript: all authors; 
administrative, technical, or material support: M.N.K., S.U.K., 
and S.H.A.; study supervision: S.U.K. and S.H.A.
REFERENCES
1. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on 
the level of circulating hepatitis B viral load. Gastroenterology 
2006;130:678-686.
2. European Association for the Study of the Liver. Electronic ad-
dress: easloffice@easloffice.eu; European Association for the Study 
of the Liver. EASL 2017 Clinical Practice Guidelines on the man-
agement of hepatitis B virus infection. J Hepatol 2017;67:370-398. 
3. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus 
statement on the management of chronic hepatitis B: a 2012 up-
date. Hepatol Int 2012;6:531-561.
4. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with 
chronic hepatitis B and advanced liver disease. N Engl J Med 
2004;351:1521-1531.
5. Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico 
P. Risk of hepatocellular carcinoma in chronic hepatitis B: assess-
ment and modification with current antiviral therapy. J Hepatol 
2015;62:956-967.
6. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. In-
cidence of hepatocellular carcinoma in chronic hepatitis B patients 
receiving nucleos(t)ide therapy: a systematic review. J Hepatol 
2010;53:348-356.
7. Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces 
hepatic events and deaths in chronic hepatitis B patients with liver 
cirrhosis. Hepatology 2013;58:1537-1547.
Kim MN, et al: Liver Cirrhosis Predicts Clinical Outcomes in Chronic Hepatitis B  205
8. Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treat-
ment reduces hepatocellular carcinoma incidence in patients with 
hepatitis B virus infection. Hepatology 2013;58:98-107.
9. Yasunaka T, Ikeda F, Wada N, et al. Entecavir reduces hepatocar-
cinogenesis in chronic hepatitis B patients. Acta Med Okayama 
2016;70:1-12.
10. Kumada T, Toyoda H, Tada T, et al. Effect of nucleos(t)ide ana-
logue therapy on hepatocarcinogenesis in chronic hepatitis B pa-
tients: a propensity score analysis. J Hepatol 2013;58:427-433.
11. Cho JY, Paik YH, Sohn W, et al. Patients with chronic hepati-
tis B treated with oral antiviral therapy retain a higher risk for 
HCC compared with patients with inactive stage disease. Gut 
2014;63:1943-1950. 
12. Park YE, Kim BK, Park JY, et al. Gamma-glutamyl transpeptidase-
to-platelet ratio is an independent predictor of hepatitis B virus-
related liver cancer. J Gastroenterol Hepatol 2017;32:1221-1229.
13. Korean Association for the Study of the Liver. KASL clinical 
practice guidelines: management of chronic hepatitis B. Clin Mol 
Hepatol 2016;22:18-75.
14. Ahn J, Lim JK, Lee HM, et al. Lower observed hepatocellular 
carcinoma incidence in chronic hepatitis B patients treated with 
entecavir: results of the ENUMERATE study. Am J Gastroenterol 
2016;111:1297-1304.
15. Bruix J, Sherman M; American Association for the Study of Liver 
Diseases. Management of hepatocellular carcinoma: an update. 
Hepatology 2011;53:1020-1022.
16. Yuen MF, Seto WK, Chow DH, et al. Long-term lamivudine thera-
py reduces the risk of long-term complications of chronic hepatitis 
B infection even in patients without advanced disease. Antivir 
Ther 2007;12:1295-1303.
17. Matsumoto A, Tanaka E, Rokuhara A, et al. Efficacy of lamivu-
dine for preventing hepatocellular carcinoma in chronic hepatitis 
B: a multicenter retrospective study of 2795 patients. Hepatol Res 
2005;32:173-184. 
18. Eun JR, Lee HJ, Kim TN, Lee KS. Risk assessment for the devel-
opment of hepatocellular carcinoma: according to on-treatment 
viral response during long-term lamivudine therapy in hepatitis B 
virus-related liver disease. J Hepatol 2010;53:118-125. 
19. Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al. Viro-
logical suppression does not prevent the development of hepato-
cellular carcinoma in HBeAg-negative chronic hepatitis B patients 
with cirrhosis receiving oral antiviral(s) starting with lamivudine 
monotherapy: results of the nationwide HEPNET. Greece cohort 
study. Gut 2011;60:1109-1116.
20. Kurokawa M, Hiramatsu N, Oze T, et al. Long-term effect of 
lamivudine treatment on the incidence of hepatocellular carci-
noma in patients with hepatitis B virus infection. J Gastroenterol 
2012;47:577-585.
21. Kim DY, Song KJ, Kim SU, et al. Transient elastography-based risk 
estimation of hepatitis B virus-related occurrence of hepatocellular 
carcinoma: development and validation of a predictive model. 
Onco Targets Ther 2013;6:1463-1469. 
22. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatol-
ogy 2009;50:661-662. 
23. Lee KS, Kim DJ; Korean Association for the Study of the Liver 
Guideline Committee. Management of chronic hepatitis B. Korean 
J Hepatol 2007;13:447-488. 
24. Chu CM, Liaw YF. Incidence and risk factors of progression to cir-
rhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 
2009;104:1693-1699.
25. Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis B 
virus are still at risk for hepatocellular carcinoma and liver-related 
death. Gastroenterology 2010;138:1747-1754.
26. Kim GA, Lim YS, Han S, et al. High risk of hepatocellular carci-
noma and death in patients with immune-tolerant-phase chronic 
hepatitis B. Gut 2018;67:945-952.
27. Wang JP, Kao FY, Wu CY, et al. Nucleos(t)ide analogues associated 
with a reduced risk of hepatocellular carcinoma in hepatitis B pa-
tients: a population-based cohort study. Cancer 2015;121:1446-1455.
28. Orito E, Hasebe C, Kurosaki M, et al. Risk of hepatocellular car-
cinoma in cirrhotic hepatitis B virus patients during nucleoside/
nucleotide analog therapy. Hepatol Res 2015;45:872-879.
29. Papatheodoridis GV, Dalekos GN, Yurdaydin C, et al. Incidence 
and predictors of hepatocellular carcinoma in Caucasian chronic 
hepatitis B patients receiving entecavir or tenofovir. J Hepatol 
2015;62:363-370. 
30. Singal AK, Salameh H, Kuo YF, Fontana RJ. Meta-analysis: the 
impact of oral anti-viral agents on the incidence of hepatocel-
lular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 
2013;38:98-106. 
31. Wong GL, Espinosa WZ, Wong VW. Personalized management of 
cirrhosis by non-invasive tests of liver fibrosis. Clin Mol Hepatol 
2015;21:200-211.
32. Martin J, Khatri G, Gopal P, Singal AG. Accuracy of ultrasound 
and noninvasive markers of fibrosis to identify patients with cir-
rhosis. Dig Dis Sci 2015;60:1841-1847. 
33. Martínez SM, Crespo G, Navasa M, Forns X. Noninvasive assess-
ment of liver fibrosis. Hepatology 2011;53:325-335. 
34. Kim MN, Kim SU, Kim BK, et al. Increased risk of hepatocellular 
carcinoma in chronic hepatitis B patients with transient elastogra-
phy-defined subclinical cirrhosis. Hepatology 2015;61:1851-1859.
35. Seo YS, Kim MN, Kim SU, et al. Risk assessment of hepatocellular 
carcinoma using transient elastography vs. liver biopsy in chronic 
hepatitis B patients receiving antiviral therapy. Medicine (Balti-
more) 2016;95:e2985.
36. Kim BK, Kim HS, Yoo EJ, et al. Risk assessment of clinical out-
comes in Asian patients with chronic hepatitis B using enhanced 
liver fibrosis test. Hepatology 2014;60:1911-1919. 
37. Suh B, Park S, Shin DW, et al. High liver fibrosis index FIB-4 is 
highly predictive of hepatocellular carcinoma in chronic hepatitis 
B carriers. Hepatology 2015;61:1261-1268.
38. Kim HS, Kim BK, Kim SU, et al. Association between level of fibro-
sis, rather than antiviral regimen, and outcomes of patients with 
chronic hepatitis B. Clin Gastroenterol Hepatol 2016;14:1647-1656.
